Related Experiment Video
Updated: Jul 30, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical
Hernando Vargas-Uricoechea1, Juan Pablo Frias2, Hernando David Vargas-Sierra3
1Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Popayán-Colombia.
The Review of Diabetic Studies : RDS
|May 15, 2023
Summary
Fixed-ratio combinations of insulin and GLP-1 receptor agonists improve glycemic control in type 2 diabetes. These combinations offer a lower risk of hypoglycemia than basal insulin and fewer gastrointestinal issues than GLP-1 receptor agonists alone.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Therapeutic failure with oral anti-diabetic agents is common in type 2 diabetes.
- Intensification strategies include basal or multiple daily insulin injections and GLP-1 receptor agonists.
- Fixed-ratio combinations of insulin and GLP-1 receptor agonists offer a novel approach to treatment intensification.
Conclusions:
- Fixed-ratio combinations are effective in intensifying type 2 diabetes treatment.
- They offer an improved safety profile regarding hypoglycemia and gastrointestinal side effects.
- These combinations are particularly beneficial for patients not achieving control with oral anti-diabetics or basal insulin, or those on GLP-1 receptor agonists plus oral anti-diabetics.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
01:16Insulin: Dosing Regimen and Adverse Effects
217
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
217
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
01:23Dipeptidyl Peptidase 4 Inhibitors
218
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
218
01:06Oral Hypoglycemic Agents: Glinides
193
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
193
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
151
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
151